DOI QR코드

DOI QR Code

파킨슨병 관련 실험 연구에서 육계의 신경 보호효과에 대한 고찰

A Review of the Neuroprotective Effects of Cinnamon in Experimental Studies on Parkinson's Disease

  • 허혜민 (우석대학교 한의과대학 한의학과) ;
  • 한주희 (우석대학교 한의과대학 한의학과) ;
  • 정민정 (우석대학교 한의과대학 소아과학교실) ;
  • 김홍준 (우석대학교 한의과대학 방제학교실) ;
  • 장인수 (우석대학교 한의과대학 내과학교실)
  • Heo, Hyemin (Dept. of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Han, Juhee (Dept. of Korean Medicine, College of Korean Medicine, Woosuk University) ;
  • Jeong, Minjeong (Dept. of Pediatrics, College of Korean Medicine, Woosuk University) ;
  • Kim, Hongjun (Dept. of Prescription, College of Korean Medicine, Woosuk University) ;
  • Jang, Insoo (Dept. of Internal Medicine, College of Korean Medicine, Woosuk University)
  • 투고 : 2020.11.20
  • 심사 : 2020.12.26
  • 발행 : 2020.12.30

초록

Objective: The purpose of this study was to investigate the effect of cinnamon on the treatment of Parkinson's disease (PD) and to introduce its use in Korea. Method: We searched the experimental studies in electronic databases (PubMed, CNKI, Wanfang, CiNii, J-STAGE, Science ON, and OASIS) using the key search terms "cinnamic acid", "cinnamon", "cinnamomum", "Parkinson's disease", "Parkinson disease", "Parkinsonism", and "dopamine". This study only involved experimental studies (in vivo and in vitro) that adopted cinnamon as a single administration and measured indicators relating to Parkinson's disease, including parkin, tyrosine hydroxylase (TH), and dopamine. Results: A Total of 11 literature studies were selected, and they all showed that treatment with cinnamon has a neuroprotective effect. Cinnamon activated neuroprotective factors and restored neurotransmitters and it reduced the rate of oxidative stress and inflammation in neurons. As a result, cell viability was upregulated, while cell apoptosis and neurodegeneration were downregulated. Five in vivo studies, through behavioral tests, also confirmed that cinnamon recovers locomotor function in PD models. Conclusion: We identified that cinnamon is an effective neural protector and improves motor performance in behavioral testing in the experimental PD studies.

키워드

참고문헌

  1. The Korean Movement Disorder Society. Report to expand the policy supporting Parkinson's disease in Korea. Seoul: 2007.
  2. Health Insurance Review and Assessment Service. Disease subclass statistics. Number of patients by year: Parkinson's disease. Available from: http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do [accessed Oct 10, 2020]
  3. Kim JH. Analysis of prescription of Parkinson's drug using HIRA-NPS data. Master s' thesis, Graduate School of Sungkyunkwan University 2020.
  4. Lee JJ. Pharmacological treatment in Parkinson's disease. J Korean Neurol Assoc 2019;37(4):335-44. doi: 10.17340/jkna.2019.4.1
  5. Guideline center for Korean Medicine. Korean medicine clinical practice guideline for Parkinson's disease. Seoul: 2017. Available from: http://www.nckm.or.kr [accessed Oct 10, 2020]
  6. Cho KH. Korean medicine treatment of Parkinson's disease. Paju: Mulgogisup; 2018, p. 123-6.
  7. Lee SH, Lim S. Clinical effectiveness of acupuncture on Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. Medicine 2017;96(3):e5836. doi: 10.1097/MD.0000000000005836
  8. Doo KH, Lee JH, Cho SY, Jung WS, Moon SK, Park JM, et al. A prospective open-label study of combined treatment for idiopathic Parkinson's disease using acupuncture and bee venom acupuncture as an adjunctive treatment. J Altern Complement Med 2015;21(10):598-603. doi: 10.1089/acm.2015.0078
  9. Hartmann A, Mullner J, Meier N, Hesekamp H, van Meerbeeck P, Habert MO, et al. Bee venom for the treatment of Parkinson disease - A randomized controlled clinical trial. PLoS One 2016;11(7):e0158235. doi: 10.1371/journal.pone.0158235
  10. Yang SB, KIm YJ, Lee HM, Lee SH, cho SY, Park JM, et al. Effects of korean medicine on postural instability and gait difficulty in patient with Parkinsonism: Retrospective Study. J Korean Med 2017;38(3):96-102. doi: 10.13048/jkm.17028
  11. Raha S, Dutta D, Roy A, Pahan K. Reduction of Lewy body pathology by oral cinnamon. J Neuroimmune Pharmacol 2020. doi: 10.1007/s11481-020-09955-2
  12. Ramazani E, YazdFazeli M, Emami SA, Mohtashami L, Javadi B, Asili J, et al. Protective effects of Cinnamomum verum, Cinnamomum cassia and cinnamaldehyde against 6-OHDA-induced apoptosis in PC12 cells. Mol Biol Rep 2020;47(4):2437-45. doi: 10.1007/s11033-020-05284-y
  13. Patel D, Jana A, Roy A, Pahan K. Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson's disease via astrocytic GDNF. J Neuroimmune Pharmacol 2019;14(3):503-18. doi: 10.1007/s11481-019-09855-0
  14. Prorok T, Jana M, Patel D, Pahan K. Cinnamic acid protects the nigrostriatum in a mouse model of Parkinson's disease via Peroxisome Proliferator-Activated Receptorα. Neurochem Res 2019;44(4):751-62. doi: 10.1007/s11064-018-02705-0
  15. Maiolo SA, Fan P, Bobrovskaya L. Bioactive constituents from cinnamon, hemp seed and polygonum cuspidatum protect against H2O2 but not rotenone toxicity in a cellular model of Parkinson's disease. J Tradit Complement Med 2018;8(3):420-7. doi: 10.1016/j.jtcme.2017.11.001
  16. Bae WY, Choi JS, Jeong JW. The neuroprotective effects of cinnamic aldehyde in an MPTP mouse model of Parkinson's disease. Int J Mol Sci 2018;19(2):551. doi: 10.3390/ijms19020551.
  17. Zeng H, He G, Huang H, Li Y. Protective effect of total flavonoids of Cinnamomi cortex on PC12 cell injured by 6-Hydroxydopamine. Zhong Yao Cai 2017;40(12):2936-40. doi: 10.13863/j.issn1001-4454.2017.12.043
  18. Khasnavis S, Pahan K. Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol 2014;9(4):569-81. doi: 10.1007/s11481-014-9552-2
  19. Shaltiel-Karyo R, Davidi D, Frenkel-Pinter M, Ovadia M, Segal D, Gazit E. Differential inhibition of α-synuclein oligomeric and fibrillar assembly in Parkinson's disease model by cinnamon extract. Biochim Biophys Acta 2012;1820(10):1628-35. doi: 10.1016/j.bbagen.2012.04.021
  20. Khasnavis S, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol 2012;7(2):424-35. doi: 10.1007/s11481-011-9286-3
  21. Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 2009;183(9):5917-27. doi: 10.4049/jimmunol.0803336
  22. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35. doi: 10.1016/S1474-4422(06)70471-9
  23. Korean medicine pharmacology Compilation committee. Korean medicine pharmacology. 4th ed. Seoul: Shinilbooks; 2015, p. 150-7.
  24. Ranasinghe P, Pigera S, Premakumara GAS, Galappaththy P, Constantine GR, Katulanda P. Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): a systematic review. BMC Complement Altern Med 2013;13(1):275 doi: 10.1186/1472-6882-13-275
  25. Neuberger JM, Schweitzer S, Rolland M, Burghard R. Effect of sodium benzoate in the treatment of atypical nonketotic hyperglycinaemia. J Inherit Metab Dis 2000;23(1):22-6. doi: 10.1023/a:1005642728513
  26. Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol 2002;7(1):27-35. doi: 10.1053/siny.2001.0085
  27. What is sodium benzoate? Everything you need to know. Healthline. last modified Jan 21, 2019. Available from: https://www.healthline.com/nutrition/sodium-benzoate [accessed Nov 12, 2020]
  28. CREB. Wikipedia. Available from: https://en.wikipedia.org/wiki/CREB [accessed Oct 11, 2020]
  29. Yoon MJ, Lee HH. The physiological function of PPARα. Biochemistry and Molecular Biology News 2004;24(1):22-31.
  30. Ministry of Food and Drug Safety. Integrated pharmaceutical information system: Cinnamon Bark. Available from: https://nedrug.mfds.go.kr/pbp/CCEKP14/selectEkpPopupList [accessed Oct 11, 2020]
  31. Choe JG. Research on the coumarin analysis in the cinnamon contained foods for standardization & specification. Korea Food & Drug Administration 2009.